Quantcast
Last updated on April 21, 2014 at 8:52 EDT

Latest ImaginAb Inc. Stories

2011-06-07 07:00:00

SAN ANTONIO, June 7, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the availability of custom radiolabeling services for proteins, peptides and other macromolecules as of the 1st of July 2011. This is part of the company's ongoing initiative to broaden the range of product and service offerings to the biopharma and research community and is synergistic with existing activities in custom antibody fragment engineering. "Over the past 18 months we have grown our core antibody...

2011-06-06 11:53:00

OXFORD, United Kingdom, June 6, 2011 /PRNewswire/ -- Oxford BioMedicaplc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc. ("ImaginAb"), a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the...

2011-06-06 07:30:00

LOS ANGELES, June 6, 2011 /PRNewswire/ -- ImaginAb, Inc. has been invited to join KeyMarker, a leading consortium of Belgian academic scientists and biotech companies for the discovery of new diagnostic and therapeutic targets for diabetes. This consortium is established under the framework of Biowin, the Health Competitiveness Cluster of the Walloon Region from Belgium. It is coordinated by IBA Molecular with Eurogentec and TraSis as industrial partners. Based on new biomarkers discovered...

2011-06-05 10:17:00

LOS ANGELES and LITTLE CHALFONT, England, June 5, 2011 /PRNewswire/ -- GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target*. "We are very pleased to have established this collaboration with GE and particularly delighted...

2011-04-18 07:00:00

LOS ANGELES, April 18, 2011 /PRNewswire/ -- ImaginAb, Inc. and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with Positron Emission Tomography (PET). "We are pleased that ImaginAb has expanded its technology portfolio and recognized the cutting-edge work being developed by the Crump Institute," said Dr....

2011-04-11 13:37:00

LOS ANGELES and KYOTO, Japan, April 11, 2011 /PRNewswire/ -- ImaginAb, Inc. and Dainippon Seiki Co., Ltd. have concluded a technology agreement around the development of automated chemistry systems for fluorination of proteins and peptides for diagnostic imaging with positron emission tomography (PET). "Over the past 18 months, our academic and pharma client base has dramatically increased and we have been developing and in-licensing novel fluorine chemistries to streamline labeling of...

2011-01-31 11:00:00

LOS ANGELES, Jan. 31, 2011 /PRNewswire/ -- ImaginAb, Inc. and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system. Leveraging Eurogentec's expertise in cGMP manufacturing of recombinant proteins, the collaboration will accelerate the development of ImaginAb's rich pipeline of...

2010-10-11 08:30:00

LOS ANGELES, Oct. 11 /PRNewswire/ -- ImaginAb, Inc. and Imanet (part of GE Healthcare) have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet(TM) network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept...

2010-05-19 11:00:00

LOS ANGELES, May 19 /PRNewswire/ -- ImaginAb, Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group of Companies) have concluded two research collaboration agreements around a clinical therapeutic antibody asset currently under development by GSK in the field of oncology. "ImaginAb is pleased to have formalized this collaboration with the GSK CIC," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Not only does GSK have an excellent biologics pipeline, but the...

2009-10-12 08:23:00

INGLEWOOD, Calif., Oct. 12 /PRNewswire/ -- ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer. BZL's technology has extensive human data, and we believe that huJ591 in...